Safety and Effectiveness of Apixaban in Very Elderly Patients With Non-valvular Atrial Fibrillation (NVAF) Compared to Warfarin Using Administrative Claims Data

CompletedOBSERVATIONAL

Enrollment

77,814

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

October 19, 2022

Study Completion Date

October 19, 2022

Conditions

Non-valvular Atrial Fibrillation

Interventions

DRUG

Warfarin

This is observational study and the patients in the warfarin cohort include those who are exposed to warfarin in the real world settings.

DRUG

Apixaban

This is observational study and the patients in the apixaban cohort include those who are exposed to apixaban in the real world settings.

Trial Locations (1)

Pfizer Site, Tokyo